ASH Annual Meeting and Exposition

The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone continued to elicit improved outcomes vs RVd alone in patients with newly diagnosed, transplant-eligible multiple myeloma, according to findings from the extended 2-year follow-up analysis of the phase 2 GRIFFIN trial.

Treatment with the CD123- and CD3-engaging bispecific antibody APVO436 caused cytokine release syndrome in approximately 1 of 5 patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome but was generally well managed with steroids.

Patients with relapsed or refractory large B-cell lymphoma experienced better quality of life when they received second-line treatment with lisocabtagene maraleucel vs standard of care.

A single infusion of ciltacabtagene autoleucel produced an overall response rate of 95% in patients with multiple myeloma who had received a median of 2 prior lines of treatment and who were refractory to lenalidomide.

The utilization of oral azacitidine as maintenance treatment in patients with acute myeloid leukemia in first remission following intensive chemotherapy continued to showcase a survival benefit over placebo.

Data from a longer follow-up analysis of the phase 1/2 CARTITUDE-1 trial demonstrated that all evaluated subgroups of patients with relapsed/refractory multiple myeloma maintained durable responses with ciltacabtagene autoleucel.

John M. Burke, MD, discusses findings from the phase 3 POLARIX trial in patients with newly diagnosed diffuse large B-cell lymphoma.

Thomas G. Martin, MD, discusses the 2-year follow-up data of the phase 1/2 CARTITUDE-1 study in relapsed/refractory multiple myeloma, that were presented during the 2021 ASH Annual Meeting & Exposition.

Cycle 1 double step-up dosing with cevostamab demonstrated encouraging activity with effective cytokine release syndrome mitigation in patients with heavily pretreated relapsed/refractory multiple myeloma, supporting further development of the dual-targeted bispecific antibody.

Acalabrutinib demonstrated a lower incidence of cardiovascular-related toxicities and a lower overall toxicity burden compared with ibrutinib in patients with chronic lymphocytic leukemia.

Acalabrutinib demonstrated an advantage in quality-adjusted survival compared with other treatments for relapsed/refractory chronic lymphocytic leukemia.

Magrolimab plus combinations of various antileukemia therapies are being investigated for their efficacy in first-line, relapsed/refractory, or maintenance treatment of acute myeloid leukemia.

High-frequency low-dose acalabrutinib and rituximab represents a feasible and effective combination for the treatment of patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.

Treatment with pacritinib, when administered at 200 mg twice daily, had a comparable safety profile to best available therapy in patients with cytopenic myelofibrosis, including those with severe thrombocytopenia.

Sabatolimab, an investigational TIM-3 monoclonal antibody, induced a median duration of response greater than 1 year for patients with very high/high-risk myelodysplastic syndrome and acute myeloid leukemia when used in combination with hypomethylating agents.

Patients with polycythemia vera who have controlled hematocrit levels, but elevated white blood counts are at an increased risk of thrombotic events, according to a presentation of the REVEAL study.

YTB323, a novel, autologous CD19-directed CAR-T cell therapy, displayed a favorable safety profile and efficacy across multiple dose levels in adult patients with relapsed/refractory diffuse large b-cell lymphoma.

Venetoclax at either 400 mg or 800 mg plus daratumumab and dexamethasone elicited deep durable responses and was associated with a tolerable safety profile in patients with t(11;14) relapsed/refractory multiple myeloma.

Prognostic awareness was associated with higher rates of psychosocial distress and symptom burden, and lower quality of life in patients with multiple myeloma.

Lower 60mg and 40mg doses of Selinexor in combination with bortezomib and dexamethasone demonstrated improved efficacy and safety vs a 100mg dose for patients with relapsed or refractory multiple myeloma.

The combination of ibrutinib and venetoclax led to a lower rate of minimal residual disease compared with fludarabine, cyclophosphamide, and rituximab in patients with treatment-naïve chronic lymphocytic leukemia, according to preliminary findings from the phase 2 ERADIC trial.

Frontline treatment with axicabtagene ciloleucel demonstrated rapid and durable responses in patients with high-risk large B-cell lymphoma.

The addition of polatuzumab vedotin-piiq to R-CHP led to a 27% reduction in the risk of progression or death vs R-CHOP in patients with previously untreated, intermediate- and high-risk diffuse large B-cell lymphoma.

As second-line treatment, tisagenlecleucel failed to demonstrate an event-free survival advantage compared with standard of care platinum-based chemotherapy followed by autologous stem cell transplant or additional chemotherapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Noa Biran, MD, discusses the results of an arm of the ongoing phase 1b/2 STOMP trial evaluating selinexor, dosed at 40 or 60 mg, in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.

Paolo Ghia, MD, PhD, discusses the results from the minimal residual disease cohort of the phase 2 CAPTIVATE study in chronic lymphocytic leukemia that were presented during the 2021 ASH Annual Meeting & Exposition.

The addition of ibrutinib to fludarabine, cyclophosphamide, and rituximab resulted in a higher rate of complete responses with bone marrow undetectable minimal residual disease in younger, fit patients with chronic lymphocytic leukemia.

Ciltacabtagene autoleucel elicited a 97.9% objective response rate and an 82.5% stringent complete response rate in patients with relapsed/refractory multiple myeloma at a median of approximately 2 years of follow-up.

Acalabrutinib, with or without obinutuzumab, induced a significant efficacy benefit for patients with treatment-naïve chronic lymphocytic leukemia compared with ibrutinib or venetoclax plus obinutuzumab, according to findings presented during the 63rd ASH Annual Meeting and Exposition.

The 60mg phase 2 dose of selinexor plus pomalidomide and dexamethasone produced more durable and deep responses than the lesser selinexor dose for relapsed or refractory multiple myeloma.